Centenial Surgical Suture Ltd. is a specialized Indian medical technology company dedicated to the development, manufacture, and supply of high-precision surgical sutures and medical devices. Positioned as a leader in the **cardiovascular suture** market, the company is currently transitioning from a traditional manufacturing entity into a **solutions-based medical device provider**. --- ### **Core Product Portfolio & Clinical Applications** The company operates as a single-segment entity focused exclusively on **Medical Devices**. Its portfolio is characterized by deep manufacturing know-how and a large, differentiated range of products designed for high-precision surgical fields. * **Cardiovascular Specialization:** A primary value driver featuring over **300 product codes** specifically engineered for complex procedures such as **CABG (Coronary Artery Bypass Grafting)**. * **Suture Classification:** The range includes **Absorbable** and **Non-absorbable** sutures, available in both **Monofilament** and **Multifilament** designs. * **Material Science:** Products utilize specialized materials including **silk, stainless steel wires**, and synthetics such as **polypropylene, polyester, and nylon**. * **Atraumatic Needles:** Continuous innovation in design and engineering provides advanced needle-suture combinations tailored for Indian surgeons. * **Broad Clinical Utility:** Beyond cardiology, the company serves **Ophthalmic, Orthopaedic, Neurological, Gynaecology, Obstetrics, Urology, Gastrointestinal, and General Surgery**. --- ### **Strategic Vertical Integration & Global Collaboration** To secure its supply chain and enhance margins, Centenial is pursuing a strategy of backward integration and international technical partnership. * **Technical Collaboration:** In **January 2024**, the company entered into a technical collaboration with **M/s. PolyMedTex GmbH (Germany)** for the manufacturing of unsterile surgical threads and sutures. * **Raw Material Self-Sufficiency:** The company has commenced manufacturing **surgical threads raw materials** internally to eliminate reliance on external suppliers and mitigate supply chain volatility. * **Solutions-Based Model:** Management is shifting the business focus from simple product sales to providing multifaceted medical solutions, supported by an internal initiative to commercialize new medical devices from overseas suppliers. --- ### **Manufacturing Infrastructure & Quality Compliance** Operations are centralized in **Maharashtra**, supported by a robust quality management system and a regional sales network. | Facility Type | Location Details | | :--- | :--- | | **Registered Office** | F-29, MIDC, Murbad, Thane 421401, Maharashtra | | **Manufacturing Units** | B-17, F-29, F-22, F-23, and F-24, MIDC, Murbad, Thane | | **Additional Site** | Village Dhavale, Ambernath, Thane, Maharashtra | | **Sales Offices** | **Mumbai** (Matunga), **Kolkata** (Kasba), and **Bengaluru** (Halasur) | **Certifications and Standards:** * **ISO Accreditations:** **ISO 9001:2015**, **ISO 13485:2016** (Medical Devices), **ISO 14001:2015** (Environment), and **ISO 45001:2018** (Health & Safety). * **Regulatory Adherence:** **WHO-GMP** certified; products conform to **Medical Device Directives 93/42/EEC** and the Indian **Medical Device Rules, 2017**. --- ### **Financial Performance & Capital Structure** Centenial maintains a **zero-debt** capital structure, providing significant financial flexibility. While the company saw strong growth in **FY 2022-23**, it faced pricing pressures in the subsequent cycle. | Metric | FY 2022-23 | FY 2021-22 | Growth (%) | | :--- | :--- | :--- | :--- | | **Total Revenue from Operations** | **₹52.66 crore** | **₹44.43 crore** | **18.52%** | | **Profit After Tax (PAT)** | **₹1.46 crore** | **₹1.07 crore** | **36.15%** | | **Debt Status** | **Zero-Debt** | **Zero-Debt** | - | | **Credit Rating (Non-Fund)** | **CRISIL A3** | **CRISIL A3+** | - | **Operational Metrics:** * **Share Dematerialisation:** As of **March 31, 2025**, **92.94%** of equity shares (**33,90,800 shares**) are dematerialised. * **MSME Relations:** Outstanding dues to MSMEs were reduced from **₹7.97 crore** to **₹4.33 crore** as of March 2025. * **Dividend Policy:** The Board has opted **not to recommend dividends**, prioritizing the conservation of resources for growth and strategic objectives. * **Borrowing Capacity:** Shareholders approved a borrowing limit of up to **₹100 crores** in **April 2024** to fund long-term objectives. --- ### **Research, Development & Operational Efficiency** The company utilizes an in-house **R&D** unit to drive process optimization and product innovation. * **Innovation Pipeline:** As of late 2023, **three new products** were under development and trials. * **Efficiency Gains:** R&D efforts have successfully reduced packaging time and power consumption. The company has implemented **LED fittings** and **capacitor banks** across facilities to maintain the power factor. * **Human Capital:** Total strength of **255 employees** (as of March 2023). The company is implementing the **Workday** platform to digitize HR management and is training staff in **"Product Thinking"** to foster a culture of modern marketing. --- ### **Risk Factors & Market Challenges** #### **1. Market Manipulation & Surveillance** The company has repeatedly alerted **SEBI** and the **BSE** regarding "unnatural and highly suspicious" trading patterns in its scrip. * **Price Rigging:** Management asserts a syndicate uses miniscule trades (**1–5 shares**) to manipulate the **Last Traded Price (LTP)**. * **Concentration:** The top five buyers/sellers often contribute over **90%** of market positive LTP variance, unrelated to company fundamentals. * **Compliance:** The company is currently dematerializing **600 physical shares** of promoter holdings to comply with **Regulation 31(2) of SEBI (LODR)**. #### **2. Competitive & Pricing Pressures** * **Irrational Pricing:** The industry faces "dumping" from foreign and domestic competitors, leading to extreme revenue pressure in **2024-2025**. * **Inventory Risk:** Profitability is impacted by **legacy input costs** due to an inventory coverage of **2-3 months**, making the company vulnerable to sudden drops in finished goods prices. #### **3. Financial & Regulatory Risks** * **Forex Exposure:** Primary exposure to **JPY** and **USD**, mitigated by using **Export Earnings** and **90-day irrevocable Letters of Credit**. * **Taxation:** Subject to **12% GST**; the company actively monitors anti-profiteering and E-Way Bill compliance. * **Cost Audit Dispute:** The company is contesting **ROC** proceedings regarding cost audits, maintaining it does not meet the **₹100 Crore** turnover threshold for mandatory auditing. #### **4. Foreign Exchange Summary** | Metric | FY 2023-24 | FY 2022-23 | | :--- | :--- | :--- | | **Foreign Exchange Earnings** | **₹98.83 Lakhs** | **₹2.04 Crore** | | **Foreign Exchange Outgo** | **₹9.36 Crore** | **₹2.76 Crore** | --- ### **Future Outlook & Targets** Centenial has identified the **2025-2026** fiscal year as a key milestone, with specific targets set for **operating income before special items**. Growth is expected to be driven by the **Technical Collaboration with Germany**, the expansion of the **cardiovascular division**, and a strategic push into **export markets** by targeting high-value strategic accounts.